Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.

ABSTRACT: Melanoma can be classified based on the detection of relevant oncogenic driver mutations. These mutations partially determine a patient's treatment options. MEK inhibitors have demonstrated little efficacy in patients with NRAS-mutated melanoma owing to primary and secondary resistance. We report two patients with NRAS-mutant metastatic melanoma with long-term response to intermittent MEK-inhibitor binimetinib therapy. Intermittent dosing schedules could play a key role in preventing resistance to targeted therapy. This article highlights the efficacy of an intermittent dosing schedule, toxicities associated with binimetinib, and possible mechanisms preventing resistance in targeted therapy. Intermittent MEK-inhibitor therapy may be considered in patients with NRAS-mutated melanoma that ha

SUBMITTER: Matter AV 

PROVIDER: S-EPMC7648363 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature